Lipids in Blood-Brain Barrier Models in vitro I: TLC and HPLC for the Analysis of Lipid Classes and Long Polyunsaturated Fatty Acids

2003 ◽  
Author(s):  
Stefanie Kramer ◽  
Johannah Hurley ◽  
N. Abbott ◽  
David Begley
Keyword(s):  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Blood Brain Barrier ◽  
Lipid Classes ◽  
Brain Barrier ◽  
Blood Brain

LIPIDS IN BLOOD–BRAIN BARRIER MODELS IN VITRO II: INFLUENCE OF GLIAL CELLS ON LIPID CLASSES AND LIPID FATTY ACIDS

2002 ◽  
Vol 38 (10) ◽  
pp. 566 ◽  
Author(s):  
STEFANIE D. KRÄMER ◽  
YANNIC B. SCHÜTZ ◽  
HEIDI WUNDERLI-ALLENSPACH ◽  
N. JOAN ABBOTT ◽  
DAVID J. BEGLEY
Keyword(s):  
Fatty Acids ◽  
Blood Brain Barrier ◽  
Glial Cells ◽  
Lipid Classes ◽  
Brain Barrier ◽  
Blood Brain

Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood–brain barrier in vitro model

2011 ◽  
Vol 42 (3) ◽  
pp. 290-299 ◽  
Author(s):  
C. Navarro ◽  
I. González-Álvarez ◽  
M. González-Álvarez ◽  
M. Manku ◽  
V. Merino ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Blood Brain Barrier ◽  
In Vitro Model ◽  
Brain Barrier ◽  
Blood Brain ◽  
Vitro Model

scholarly journals Biochemical‐ and Biophysical‐Induced Barriergenesis in the Blood–Brain Barrier: A Review of Barriergenic Factors for Use in In Vitro Models

2021 ◽  
Vol 1 (5) ◽  
pp. 2170051
Author(s):  
Christina L. Schofield ◽  
Aleixandre Rodrigo-Navarro ◽  
Matthew J. Dalby ◽  
Tom Van Agtmael ◽  
Manuel Salmeron-Sanchez
Keyword(s):  
Blood Brain Barrier ◽  
In Vitro Models ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals Miniaturization and Automation of a Human In Vitro Blood–Brain Barrier Model for the High-Throughput Screening of Compounds in the Early Stage of Drug Discovery

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 892
Author(s):  
Elisa L. J. Moya ◽  
Elodie Vandenhaute ◽  
Eleonora Rizzi ◽  
Marie-Christine Boucau ◽  
Johan Hachani ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Blood Brain Barrier ◽  
Early Stage ◽  
Molecular Transport ◽  
Brain Barrier ◽  
Blood Brain ◽  
Cns Drugs ◽  
The Impact ◽  
The Brain

Central nervous system (CNS) diseases are one of the top causes of death worldwide. As there is a difficulty of drug penetration into the brain due to the blood–brain barrier (BBB), many CNS drugs treatments fail in clinical trials. Hence, there is a need to develop effective CNS drugs following strategies for delivery to the brain by better selecting them as early as possible during the drug discovery process. The use of in vitro BBB models has proved useful to evaluate the impact of drugs/compounds toxicity, BBB permeation rates and molecular transport mechanisms within the brain cells in academic research and early-stage drug discovery. However, these studies that require biological material (animal brain or human cells) are time-consuming and involve costly amounts of materials and plastic wastes due to the format of the models. Hence, to adapt to the high yields needed in early-stage drug discoveries for compound screenings, a patented well-established human in vitro BBB model was miniaturized and automated into a 96-well format. This replicate met all the BBB model reliability criteria to get predictive results, allowing a significant reduction in biological materials, waste and a higher screening capacity for being extensively used during early-stage drug discovery studies.

scholarly journals Low nanogel stiffness favors nanogel transcytosis across an in vitro blood–brain barrier

2021 ◽  
Vol 34 ◽  
pp. 102377
Author(s):  
Laís Ribovski ◽  
Edwin de Jong ◽  
Olga Mergel ◽  
Guangyue Zu ◽  
Damla Keskin ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Blood Brain
Sign in / Sign up

Export Citation Format

Share Document